PetrichorCapital Partners
PetrichorCapital Partners
Provides structured growth capital to facilitate the adoption of healthcare innovations
Petrichor Capital Partners makes structured investments across the global healthcare sector, with a focus on biopharmaceuticals, medical technology, diagnostics/tools, and tech-enabled services.
We provide growth investment solutions for late and commercial-stage companies.
We work with both public and private companies to support their long-term growth efforts and have deep experience with acquisitions, research & development activities, and commercial launches or expansions, among other situations.
Our investments enable leading healthcare innovators to reach the next stage of their evolution. Petrichor acts as a strategic advisor, partnering with management, Boards, and other investors to help ensure the success of our companies.
Petrichor Capital Partners in practice
Flexible Structures
Debt, equity and other structures tailored to a company’s needs.
High Growth Companies
Focused on late-stage or commercial public or private biopharma, medtech, and diagnostics companies, among others, providing capital for growth, M&A, and/or product development or launch, and beyond.
Enabling Long-Term Growth
Petrichor serves as value-added partner to execute long-term strategic vision.
Meet the team
The team has led over 125 investments, representing more than $6 billion of invested capital, and has sat on over 55 boards.
Meet the teamPortfolio
Discover the incredible companies that make up the Petrichor Capital Partners fund.
View portfolioNews
Read all newsFennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
August 2024
Read more on
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 2024
Read more on
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 2024
Read more on
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 2024
Read more on
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
June 2024
Read more on
Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
June 2024
Read more on